Macitentan

Таблетки By prescription

An endothelin-1 receptor antagonist capable of binding to endothelin receptor types A and B. Endothelin-1 mediates a variety of effects including vasoconstriction, induction of fibrosis, cell proliferation, hypertrophy, and inflammation.

Macitentan

Indications

Macitentan, as monotherapy or as part of combination therapy, is indicated for the long-term treatment of pulmonary arterial hypertension (LAH) in adult patients with World Health Organisation (WHO) functional class (FC) II and III, including:
- idiopathic and hereditary LAH;
- LAH associated with connective tissue diseases;
- LAH associated with compensated simple congenital heart disease.

Contraindications

- Hypersensitivity to macitentan or to any of the excipients,
listed in section 6.1;
- Pregnancy;
- Breastfeeding;
- Use of the drug in women with preserved childbearing potential who do not use reliable contraceptive methods;
- Severe degree of hepatic insufficiency (10 points and higher on the Child-Pugh scale), both in case of diagnosed liver cirrhosis and without it;
- Initial increase in the activity of "hepatic" transaminases alanine aminotransferase (ALT) and/or aspartate aminotransferase (ACT) more than 3 times the upper limit of normal (ULN);
- Severe renal insufficiency (creatinine clearance <30 ml/min), including if dialysis is required. including if dialysis is required (no clinical data).

Usage

Inside. The film-coated tablet is not intended to be broken, it should be swallowed whole, drinking enough water. The drug Macitentan should be taken every day at the same time, regardless of the time of food intake.

Download full instruction

Report undesirable reaction

If you have information about undesirable reaction after taking the drug

Hotline +7 (495) 984-28-47

Report

Have questions? Contact Us

Has contraindications. Needs specialist overview.

Please read our privacy policy

The present personal data processing policy is drawn up in accordance with the requirements of the Federal Law of July 27, 2006. No. 152-FЗ “On Personal Data” and determines the procedure for processing personal data and measures to ensure the security of personal data of Mir-Pharm LLC (hereinafter referred to as the Operator).

The operator sets as his most important goal and condition for the implementation of his activities the respect for the rights and freedoms of man and citizen in the processing of his personal data, including the protection of the rights to privacy, personal and family confidentiality.

The Operator's policy regarding the processing of personal data (hereinafter - the Policy) applies to all information that the Operator can receive about visitors of the website https://mirpharm.ru.

The user can get any clarification on issues of interest regarding the processing of his personal data by contacting the Operator via e-mail info@mirpharm.ru.

The current version of the Policy is located in free access on the Internet at https://mirpharm.ru/policy.

This document will reflect any changes in the policy of processing personal data by the Operator. The policy is valid indefinitely until it is replaced with a new version.